Original Article

CME Article: Examination of the Patient and Hospitalization Characteristics of 30-Day SCD Readmissions

Authors: C. Patrick Carroll, MD, Carlton Haywood, PhD, MA, Sophie M. Lanzkron, MD, MHS

Abstract

Objectives: Sickle cell disease (SCD) is associated with a high level of emergency department and hospital utilization, as well as a high rate of hospital readmissions. At Johns Hopkins Hospital, as at other institutions, SCD accounts for a large proportion of readmissions. Our study examined patient and hospitalization factors involved in readmissions at Johns Hopkins Hospital.

Methods: Patients at the Johns Hopkins Sickle Cell Center for Adults with a readmission in fiscal year 2011 were compared with an age- and sex-matched sample of clinic patients for comorbidities, complications, and prior utilization. Hospitalizations that were followed by readmissions were compared with those that were not as to admitting service, length of stay, and average daily opioid dose.

Results: Patients with readmissions had more complications and comorbidities and much higher prior utilization than typical clinic patients, whereas hospitalizations that were followed by readmissions had a longer length of stay but similar opioid doses.

Conclusions: For patients with SCD with a high volume of hospital use, readmissions may be a natural consequence of a high-admission frequency associated with greater disease severity and higher comorbidity.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Axon RN, Williams MV. Hospital readmission as an accountability measure. JAMA 2011;305:504-505.
 
2. Donzé J, Aujesky D, Williams D, et al. Potentially avoidable 30-day hospital readmissions in medical patients: derivation and validation of a prediction model. JAMA Intern Med 2013;173:632-638.
 
3. Burke RE, Donzé J, Schnipper JL. Contribution of psychiatric illness and substance abuse to 30-day readmission risk. J Hosp Med 2013;8:450-455.
 
4. Berkowitz RE, Fang Z, Helfand BK, et al. Project ReEngineered Discharge (RED) lowers hospital readmissions of patients discharged from a skilled nursing facility. J Am Med Dir Assoc 2013;14:736-740.
 
5. Shah MN, Stoev IT, Sanford DE, et al. Are readmission rates on a neurosurgical service indicators of quality of care? J Neurosurg 2013;119:1043-1049.
 
6. Shorr AF, Zilberberg MD, Reichley R, et al. Readmission following hospitalization for pneumonia: the impact of pneumonia type and its implication for hospitals. Clin Infect Dis 2013;57:362-367.
 
7. Coller RJ, Klitzner TS, Lerner CF, et al. Predictors of 30-day readmission and association with primary care follow-up plans. J Pediatr 2013;163:1027-1033.
 
8. Kociol RD, Liang L, Hernandez AF, et al. Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days. Am Heart J 2013;165:987-994.e1.
 
9. Hasan O, Meltzer DO, Shaykevich SA, et al. Hospital readmission in general medicine patients: a prediction model. J Gen Intern Med 2010;25:211-219.
 
10. Benbassat J, Taragin M. Hospital readmissions as a measure of quality of health care: advantages and limitations. Arch Intern Med 2000;160:1074-1081.
 
11. Oduyebo I, Lehmann CU, Pollack CE, et al. Association of self-reported hospital discharge handoffs with 30-day readmissions. JAMA Intern Med 2013;173:624-629.
 
12. Kilcup M, Schultz D, Carlson J, et al. Postdischarge pharmacist medication reconciliation: impact on readmission rates and financial savings. J Am Pharm Assoc (2003) 2013;53:78-84.
 
13. Kwok T, Lum CM, Chan HS, et al. A randomized, controlled trial of an intensive community nurse-supported discharge program in preventing hospital readmissions of older patients with chronic lung disease. J Am Geriatr Soc 2004;52:1240-1246.
 
14. Weinberger M, Oddone EZ, Henderson WG. Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med 1996;334:1441-1447.
 
15. Costantino ME, Frey B, Hall B, et al. The influence of a postdischarge intervention on reducing hospital readmissions in a Medicare population. Popul Health Manag 2013;16:310-316.
 
16. Andersen HE, Schultz-Larsen K, Kreiner S, et al. Can readmission after stroke be prevented? Results of a randomized clinical study: a postdischarge follow-up service for stroke survivors. Stroke 2000;31:1038-1045.
 
17. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-1195.
 
18. Centers for Medicare & Medicaid Services. Readmissions reduction program. https://www.cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps/readmissions-reduction-program.html. Accessed July 18, 2016.
 
19. Carroll CP, Haywood C, Jr Fagan P, et al. The course and correlates of high hospital utilization in sickle cell disease: evidence from a large, urban Medicaid managed care organization. Am J Hematol 2009;84:666-670.
 
20. Carroll PC, Haywood C, Jr Hoot MR, et al. A preliminary study of psychiatric, familial, and medical characteristics of high-utilizing sickle cell disease patients. Clin J Pain 2013;29:317-323.
 
21. Brousseau DC, Owens PL, Mosso AL, et al. Acute care utilization and rehospitalizations for sickle cell disease. JAMA 2010;303:1288-1294.
 
22. Carroll CP, Haywood C, Jr Lanzkron S. Prediction of onset and course of high hospital utilization in sickle cell disease. J Hosp Med 2011;6:248-255.
 
23. Elixhauser A, Steiner C. Readmissions to U.S. hospitals by diagnosis, 2010. Statistical Brief #153. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb153.pdf. Published April 2013. Accessed July 18, 2016.
 
24. Venables WN, Ripley BD. Modern Applied Statistics with S (Statistics and Computing). New York: Springer, 2010.
 
25. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 6th ed. Chicago: American Pain Society, 2008.
 
26. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991;325:11-16.
 
27. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-1644.
 
28. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-1322.
 
29. Smith WR, Ballas SK, McCarthy WF, et al. The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Med 2011;12:697-705.
 
30. Lanzkron S, Carroll CP, Haywood C Jr. The burden of emergency department use for sickle-cell disease: an analysis of the national emergency department sample database. Am J Hematol 2010;85:797-799.
 
31. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol 2005;79:17-25.